122 Carcinoma of Unknown Primary
19. Carcinoma of Unknown Primary
19.1 General Considerations
The selection of a possible therapy regimen should take into consideration the most probable localization and the histology of the primary.
19.2 paclitaxel + carboplatin + etoposide
|
Paclitaxel 200 mg /m2 i.v. ( 1 h inf) d 1 |
|
Carboplatin AUC = 6 i.v.(20-30 min inf) d 1 |
|
Etoposide 50 mg p.o. d 1,3,5,7,9 and 100 mg p.o. d 2,4,6,8,10 |
To be repeated every 3 weeks
Literature:
GRECO et al, Cancer 89 (2000): 2655-2660
HAINSWORTH et al, J. Clin. Oncol. 15 (1997): 2385 – 2393
19.3 Cisplatin- based combination chemotherapy
Cisplatin, vinblastine, bleomycin ± doxorubicin or cisplatin , etoposide ± bleomycin .
Usual dose of cisplatin 20 mg/m2 i.v. days 1 – 5, etoposide 100 mg/m2 i.v. days 1 – 5 , bleomycin 30 U/Wk. If response after two courses at three week intervals, four courses were given.
Literature:
HAINSWORTH et al, J. Clin. Oncol. 10 (1992): 912 – 922
19.4 Docetaxel + carboplatin
|
Docetaxel 65 mg/m2 i.v. d 1 |
|
Carboplatin AUC = 6 i.v. d 1 |
To be repeated every 3 weeks (max 8 courses in stable or responding patients)
Literature:
GRECO et al, Ann. Oncol. 11 (2000): 211 – 215
19.5 TFL
|
Paclitaxel 175 mg /m2 i.v.(3 h inf) d 1 |
|
5 – Fluorouracil 350 mg/m2 i.v. (30 –60 min inf) d 1 – 3 |
|
Folinic acid 300 mg i.v. (30 – 60 min inf) d 1 – 3 |
To be repeated every 4 weeks
Literature:
DOWELL et al, Cancer 91 (2001): 592 – 597
19.6 VAC
|
Vincristine 1.4 mg/m2 i.v. d 1 |
|
Doxorubicin 50 mg/m2 i.v. d 1 |
|
Cyclophosphamide 500 mg/m2 i.v. d 1 |
To be repeated every 3 weeks
Literature:
ANDERSEN et al, Eur. J. Cancer Clin. Oncol. 19 (1983): 49 – 52